Dyadic International Posts 3.09M Revenue but Extends Net Loss to 7.36M with First Commercial Product Launch
Dyadic International generated $3.09 million in 2025 revenue, down from $3.5 million in 2024, and recorded a $7.36 million net loss, up from $5.81 million. Cash stood at $8.6 million as the company launched its first commercial recombinant human albumin product and secured $1.86 million in grant funding.
1. Financial Performance
Dyadic posted $3.09 million in revenue for the year ended December 31, 2025, down from $3.5 million in 2024. Net loss widened to $7.36 million ($0.23 per share) versus $5.81 million ($0.20 per share) a year earlier; operating activities used $5.7 million in cash while cash and equivalents totaled $8.6 million, and R&D revenue fell to $0.6 million from $1.2 million.
2. Commercial Product Launch
The company launched its first commercial product, recombinant human albumin, in partnership with Proliant Health & Biologicals. This offering is expected to generate recurring revenue as customers qualify it for their workflows, with management targeting additional distribution agreements to scale volume.
3. Grant Partnerships
Dyadic secured $1.86 million in grant revenue from collaborations with the Gates Foundation and CEPI, providing non-dilutive funding. These grants support ongoing biopharmaceutical programs and validate the platform’s ability to advance vaccines and therapeutics.
4. Outlook and Challenges
Management warns of a slow ramp in product revenues as customers complete qualification processes, making breakeven timing dependent on adoption rates. The company remains in transition, focusing on commercializing its portfolio across life sciences, nutrition and bioindustrial segments while monitoring its cash runway.